Tech Company Financing Transactions
Noema Pharma Funding Round
On 12/11/2024, Noema Pharma raised Series B funding from EQT Life Sciences.
Transaction Overview
Company Name
Announced On
12/11/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support its four active Phase 2 trials, with key data readouts anticipated in 2025, including additional development activities for basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC); gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Barfüsserplatz 3
Basel, 4051
CH
Basel, 4051
CH
Phone
Undisclosed
Website
Email Address
Overview
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema's research and development is focused on understanding and meeting patient needs using our novel therapies.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/11/2024: Flare venture capital transaction
Next: 12/11/2024: TrueWind venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs